Merck KGaA reported a 16.6% decline in contract manufacturing due to an unrepeated Covid-19 contract, though overall life ...

Investing.com -- Shares of Merck KGaA (ETR: MRCG) fell over 4% on Thursday following a mixed reception to its third-quarter ...

This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held ...

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

At the core of this is a recovery for its life science unit, which dipped last year as its boom from components for Covid ...

Merck, which previously predicted 2024 sales between 20.7 billion ... continues to regain ground from a slump after the end ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

This eases the user's understanding of the market thoroughly, while also gaining knowledge about Anxiety Disorder Treatment market opportunities and the dominant players Pfizer Inc, Merck KGaA ...

BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

Chronic Lower Back Pain (CLBP) market Research Report Covers, Future Trends, Past, Present Data and Deep Analysis ...

Orna Therapeutics, part of a buzzy cohort of biotech companies established in the wake of the Covid pandemic, has cut more ...